Bassel Nazha, MD, MPH

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (152 ratings)

Role

Medical Oncology
Specialty

Adrenal Cancer Bladder Cancer Kidney (Renal) Cancer Penile Cancer Prostate Cancer Testicular Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2020

Request Appointment

Background

Bassel Nazha, MD, MPH, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nazha joined the clinical staff at Winship Cancer Institute of Emory Unviersity as a practicing physician in 2020. A medical oncologist, he specializes in the treatment of genitourinary cancers.

Dr. Nazha received his MD from the American University of Beirut in Beirut, Lebanon. He completed a clinical fellowship in Hematology/Oncology at Emory University School of Medicine in Atlanta, Georgia, where he was Chief Fellow in his final year. His postgraduate medical education also included residency training at Staten Island University Hospital - Hofstra Northwell School of Medicine in Staten Island, New York. Dr. Nazha received an MPH in Health Policy and Management from Columbia University in New York, New York. He also completed a Bachelor of Science in Biology at McGill University in Montreal, Canada, graduating with Great Distinction.

Dr. Nazha's research area of interest is working on novel therapeutic agents and biomarker development in genitourinary oncology. He is particularly interested in systemic treatment modalities that allow achieving higher cure rates in the non-metastatic setting, as part of a perioperative approach (neoadjuvant and adjuvant). In parallel, he is focused on conducting outcomes research to elucidate treatment efficacy in real-world settings and on minority enrollment in cancer clinical trials.

Titles & Roles

Assistant Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology/Oncology, 2020
Emory University School of Medicine
Residency, Internal Medicine & Psychiatry, 2017
Staten Island Univ. Hosp
Medical Education, , 2013
American University of Beirut Faculty of Medicine

Board Certifications

Hematology
American Board of Internal Medicine, 2020
Medical Oncology
American Board of Internal Medicine, 2020
Internal Medicine
American Board of Internal Medicine, 2017

View Current Clinical Trials


Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Phase II Conditions Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Phase II Conditions Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Phase II/III Conditions Renal Pelvis and Ureter Urothelial Carcinoma Location Emory University Hospital Midtown, Winship Cancer Institute
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Phase II Conditions Prostate Cancer Metastatic, Neuroendocrine Tumors Location Emory University Hospital Midtown, Winship Cancer Institute, Grady Health System
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Phase II Conditions Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute

Title/Journal	Authors	Publication Date
Billing for Electronic Patient-Physician Communications: An Ethical Analysis. JCO oncology practice	CH Rhee, JT Brown, A Lang, RD Pentz, B Nazha	09/04/2024
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. The oncologist	D Chukkalore, K MacDougall, V Master, MA Bilen, B Nazha	21/02/2024
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy. Clinical genitourinary cancer	EH Nicaise, BN Schmeusser, A Ali, E Midenberg, AR Palacios, B Hartsoe, E Kearns, S Ambadi, DH Patil, SS Joshi, VM Narayan, SP Psutka, B Nazha, JT Brown, K Ogan, MA Bilen, VA Master	16/02/2024
Neoadjuvant Platinum-Based chemotherapy and lymphadenectomy for penile cancer: an international, Multi-Institutional, Real-World study. Journal of the National Cancer Institute	KM Rose, R Pham, NM Zacharias, F Ionescu, M Paravathaneni, KA Marchetti, D Sanchez, A Mustasam, R Sandstrom, R Vikram, J Dhillon, P Rao, A Schneider, L Pagliaro, C Alifrangis, M Albersen, E Roussel, VA Master, B Nazha, C Hernandez, KA Moses, C Protzel, J Montgomery, M Angel, M Tobias-Machado, PE Spiess, CA Pettaway, J Chahoud	16/02/2024
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer	B Nazha, T Zhuang, S Wu, JT Brown, D Magee, BC Carthon, O Kucuk, C Nabhan, PC Barata, EI Heath, CJ Ryan, RR McKay, VA Master, MA Bilen	15/12/2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. The oncologist	GE Sanda, JM Shabto, S Goyal, Y Liu, DJ Martini, B Nazha, JT Brown, LB Yantorni, G Anne Russler, S Caulfield, SS Joshi, VM Narayan, H Kissick, K Ogan, VA Master, BC Carthon, O Kucuk, MA Bilen	11/12/2023
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression. Cancers	A Hadadi, HB Krause, A Elliott, JT Brown, B Nazha, LR Harik, BC Carthon, B Miron, C Nabhan, PC Barata, M Saleh, Y Yang, RR McKay, MA Bilen	06/12/2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. Journal of the National Cancer Institute	T El Zarif, AH Nassar, GR Pond, TZ Zhuang, V Master, B Nazha, S Niglio, N Simon, AW Hahn, CA Pettaway, SM Tu, N Abdel-Wahab, M Velev, R Flippot, S Buti, M Maruzzo, A Mittra, J Gheeya, Y Yang, PA Rodriguez, D Castellano, G de Velasco, G Roviello, L Antonuzzo, RR McKay, B Vincenzi, A Cortellini, G Hui, A Drakaki, M Glover, AR Khaki, E El-Am, N Adra, TH Mouhieddine, V Patel, A Piedra, A Gernone, NB Davis, H Matthews, MR Harrison, R Kanesvaran, GC Giudice, P Barata, A Farolfi, JL Lee, MI Milowsky, C Stahlfeld, L Appleman, JW Kim, D Freeman, TK Choueiri, PE Spiess, A Necchi, AB Apolo, GP Sonpavde	06/12/2023
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match? Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JT Brown, B Nazha, MA Bilen	10/05/2023
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	TZ Zhuang, D Ravindranathan, Y Liu, DJ Martini, JT Brown, B Nazha, G Russler, LB Yantorni, S Caulfield, BC Carthon, O Kucuk, VA Master, MA Bilen	17/03/2023
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of immunotherapy and precision oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, EE Hitron, GA Russler, L Yantorni, S Caulfield, JT Brown, JM Goldman, B Nazha, BC Carthon, WB Harris, O Kucuk, VA Master, MA Bilen	01/08/2022
Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis. Cancers	B Nazha, C Zhang, Z Chen, C Ragin, TK Owonikoko	30/06/2022
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells. Nature communications	M Boya, T Ozkaya-Ahmadov, BE Swain, CH Chu, N Asmare, O Civelekoglu, R Liu, D Lee, S Tobia, S Biliya, LD McDonald, B Nazha, O Kucuk, MG Sanda, BB Benigno, CS Moreno, MA Bilen, JF McDonald, AF Sarioglu	13/06/2022
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. Cancers	TZ Zhuang, K Case, TA Olsen, JT Brown, BC Carthon, O Kucuk, J Goldman, W Harris, MA Bilen, B Nazha	10/06/2022
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma. The oncologist	B Nazha, TZ Zhuang, HI Dada, LM Drusbosky, JT Brown, D Ravindranathan, BC Carthon, O Kucuk, J Goldman, VA Master, MA Bilen	08/06/2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urologic oncology	A Hadadi, KE Smith, L Wan, JR Brown, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, Y Liu, MA Bilen	01/06/2022
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer	DJ Martini, ST Evans, Y Liu, JM Shabto, OE Uner, TA Olsen, JT Brown, GA Russler, L Yantorni, S Caulfield, JM Goldman, B Nazha, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen	01/02/2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in endocrinology	TA Olsen, TZ Zhuang, S Caulfield, DJ Martini, JT Brown, BC Carthon, O Kucuk, W Harris, MA Bilen, B Nazha	01/01/2022
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report. Frontiers in oncology	TZ Zhuang, L Harik, S Force, A Hadadi, MA Bilen, JT Brown, BC Carthon, J Goldman, O Kucuk, VA Master, B Nazha	01/01/2022
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, JM Shabto, S Goyal, Y Liu, TA Olsen, ST Evans, BL Magod, D Ravindranathan, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, SS Joshi, HT Kissick, KE Ogan, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	01/12/2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. The oncologist	KER Smith, JT Brown, L Wan, Y Liu, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, MA Bilen	01/11/2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, S Goyal, Y Liu, ST Evans, TA Olsen, K Case, BL Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, WB Harris, HT Kissick, VA Master, O Kucuk, BC Carthon, MA Bilen	01/10/2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Journal for immunotherapy of cancer	JT Brown, Y Liu, JM Shabto, D Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, L Yantorni, SS Joshi, H Kissick, K Ogan, B Nazha, BC Carthon, O Kucuk, WB Harris, VA Master, MA Bilen	01/07/2021
Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link? Cancer	B Nazha, MA Bilen	01/05/2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Frontiers in oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, HT Kissick, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	01/01/2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Frontiers in oncology	TA Olsen, DJ Martini, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, WB Harris, O Kucuk, BC Carthon, VA Master, B Nazha, MA Bilen	01/01/2021
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. Cancer	B Nazha, S Goyal, Z Chen, A Engelhart, JW Carlisle, TJ Beardslee, H Gill, L Odikadze, Y Liu, MK Mishra, SS Ramalingam, TK Owonikoko	01/12/2020
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for immunotherapy of cancer	S Pakkala, K Higgins, Z Chen, G Sica, C Steuer, C Zhang, G Zhang, S Wang, MS Hossain, B Nazha, T Beardslee, FR Khuri, W Curran, S Lonial, EK Waller, S Ramalingam, TK Owonikoko	01/12/2020

Awards

Winship Invest$ Pilot Grant Award, 2021
Nell W. and William Simpson Elkin Fellowship, Winship Cancer Institute of Emory University, 2019
Staten Island University Hospital Resident Physician Annual Research Award, 2016 – 2017
Academy of Medicine of Richmond Best Original Research, 2017
Academy of Medicine of Richmond Grand Prize Literature Review, 2016

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	10/05/2024	Dr Bassel Nazha and Nurse Jerusalem were the best and warmest healthcare pro's i've met. Cheers to them.
One star One star One star One star One star	08/03/2024	Dr Nazha is probably one of the most capable doctors that I've ever been to and as far as I'm concerned he will be my Doctor concerning relative issues as long as I live again, thank you for asking
One star One star One star One star One star	08/03/2024	EXCEPTIONAL CARE
One star One star One star One star One star	11/01/2024	Good
One star One star One star One star One star	15/11/2023	All treatments seem to be working well.
One star One star One star One star One star	06/11/2023	Extremely satisfied with Dr. Nazha's careful listening to my concerns, providing treatment options, patiently listening to my wife's concerns and offering his valuable advice. I am very impressed by his mannerism and would definitely recommend him.
One star One star One star One star One star	25/10/2023	Very good
One star One star One star One star One star	19/10/2023	Emory has the best team there is.
One star One star One star One star One star	22/09/2023	Good experience
One star One star One star One star One star	14/09/2023	Emory staff and Dr Nazha"s group are outstanding communicators The relief they provide by their quick response to questions and concerns is in itself a healing medicine. Stress relief promotes healing.
One star One star One star One star One star	06/09/2023	Everyone was great!
One star One star One star One star One star	30/08/2023	My assigned Physician listens to me wanted to hear my story on my past treatments for my on illness. This was great.
One star One star One star One star One star	27/08/2023	Listens to my questions, gives reasonable advice.
One star One star One star One star One star	11/08/2023	Dr Nazha was very cocerned and thorough.
One star One star One star One star One star	02/08/2023	I appreciate the care provided by the Doctor
One star One star One star One star One star	19/05/2023	I would recommend my doctor to everyone
One star One star One star One star One star	18/05/2023	Dr Nazha is always clear and concerned Good explanation of options.
One star One star One star One star One star	10/05/2023	Dr Nazha is amazing. He came and talked to me in the lobby when he arrived before my appointment started. That impressed me and made me feel as more than just another patient
One star One star One star One star One star	10/05/2023	Been great so far
One star One star One star One star One half star	05/04/2023	So far I've felt good about the care of my doctor and his dedication to my welfare.
One star One star One star One star One star	17/02/2023	My Doctor was extremely informative and helpful
One star One star One star One star One star	15/01/2023	We cannot say enough about the quality of the services we have had at Emory.
One star One star One star One star One star	06/01/2023	Dr. Nazha was fantastic about informing about my scans and blood work. Questions were answered before I asked them
One star One star One star One star One star	28/10/2022	Dr. Bassel Lazha was passionate and had a caring mindset.
One star One star One star One star One star	26/10/2022	Great
One star One star One star One star One star	31/08/2022	Very nice p
One star One star One half star Empty star Empty star	21/08/2022	Oh. I found him to be very cold. Showed no signs of empathy
One star One star One star One star One star	02/07/2022	We appreciate the the confidence, calm, and hope that Dr. Nazha provided us.